Plasminogen and progression of proteinuric kidney (glomerular) disease
Plasminogen in glomerular disease progression
['FUNDING_R01'] · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · NIH-11058904
This work looks at whether a protein called plasminogen damages the kidney's filtering cells and whether blocking it could help people with proteinuric kidney disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11058904 on ClinicalTrials.gov |
What this research studies
You may be asked to give urine (and in some cases biopsy) samples so researchers can measure plasminogen using a new electro-chemiluminescent urine test. Lab studies will model how plasminogen harms podocytes, the kidney's filter cells, and test whether drugs related to amiloride can protect those cells. The team will link urine plasminogen levels to patient outcomes in existing cohorts to see if the marker predicts progression to end-stage kidney disease. Together the lab and patient-sample work aim to show whether plasminogen is both a useful biomarker and a target for treatment.
Who could benefit from this research
Good fit: People with proteinuric kidney disease and measurable albuminuria who can provide urine samples and clinical follow-up, and in some cases have had or agree to kidney biopsy, are the ideal candidates.
Not a fit: People without proteinuria or whose kidney problems are not due to glomerular disease are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could provide a urine test to identify people at high risk of kidney failure and point to drugs that protect the kidney's filtering cells.
How similar studies have performed: The team previously developed a urine ECLIA for plasminogen that showed promise in predicting progression to ESKD, but therapeutic targeting of plasminogen in patients remains largely untested.
Where this research is happening
NEW YORK, UNITED STATES
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CAMPBELL, KIRK N — ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- Study coordinator: CAMPBELL, KIRK N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.